Navigation Links
DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting

SAN FRANCISCO, July 19, 2011 /PRNewswire/ -- DecisionView Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the release of StudyOptimizer 4.3, the latest version of the company's flagship solution for patient enrollment planning, tracking and forecasting.

By providing greater visibility into site performance and cost projections, StudyOptimizer 4.3 significantly improves the ability of global pharmaceutical customers to optimize enrollment plans and deliver clinical trials on time and on budget. And with added support for clustered deployments, enterprise customers get improved performance and reliability, particularly for larger global implementations.

"Drug manufacturers are under increasing market pressure to improve enterprise agility, develop drugs faster, and lower costs," said Alan Louie, Research Director at IDC Health Insights. "The key to enabling effective clinical development transformation is improved operational excellence, in large part driven by better access to and exploitation of organizational data at all levels of the organization. DecisionView is one of the technology vendors delivering on this promise by providing real-time access to clinical enrollment performance data and supporting actionable analytics to reduce risk and increase speed in strategic decision making at all levels of the organization."

StudyOptimizer 4.3 delivers the following compelling new capabilities:

Trial Cost Visibility

The Enrollment & Treatment Cost Analysis capabilities automatically calculate planned, current and projected costs based on assumptions entered for each country participating in a trial. This analysis is presented visually, showing these cost elements over time at specific milestone points (such as Last Patient Screened and Last Patient Randomized), and broken down across regions and countries. Intuitive cost visualization adds significant value by enabling users to quickly assess costs at a glance, which is particularly useful for trials where an over-enrollment strategy is employed.

Site Performance Insights

The StudyOptimizer 4.3 'Sites View' feature has been enhanced to include additional insights on the most recent screening and randomization activity for each site, so trial managers can quickly assess which sites are encountering enrollment problems.

Enhanced scalability and performance

With the StudyOptimizer 4.3 release, customers can now run the application distributed across multiple "cluster nodes" simultaneously, providing improved performance and reliability, particularly for larger implementations.

Global Visibility Into Trial Performance

In StudyOptimizer 4.3, customers have portal-based access to two key charts:

"StudyOptimizer has quickly become a trusted 'source of truth' for our customers because it provides up-to-date information about where trial enrollment is, where it's supposed to be, and where it will end up – all in one place," said Linda Drumright, President and Chief Executive Officer at DecisionView. "StudyOptimizer 4.3 deepens that source of truth by providing visibility into additional key areas.  Now users can evaluate performance on a cost basis as well as time, diagnose site performance more granularly, and share StudyOptimizer information across the enterprise more readily through their enterprise portal strategies."


DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView's flagship solution, StudyOptimizer, helps organizations optimize clinical trial enrollment by aggregating patient recruitment data from multiple sources and providing analytics, visualizations, and predictive scenario modeling that delivers unique and actionable insight. StudyOptimizer is used by 8 of the top 10 global pharmaceutical companies, and has been used on over 1,250 clinical studies with over 450,000 subjects enrolled in 17 different therapeutic areas across 91 different countries. Investors in the company include Granite Ventures and Aeris Capital. For additional information about DecisionView, go to or call 415-538-1800.

SOURCE DecisionView Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DecisionView Launches StudyOptimizer(TM) 4
2. DecisionView to Create Clinical Trial Enrollment Benchmarks
3. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
4. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
5. Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
6. Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials
7. ClinOps, LLC Enhances Senior Management Team With Addition of Connie Andrews as Senior Vice President of Clinical Operations
8. Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities
9. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
10. Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings
11. Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities
Post Your Comments:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):